Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo
This study provides a strong pre-clinical rationale for the clinical investigation neratinib and dasatinib in HER2+ breast cancer.
Authors
- Amira F. Mahdi (ORCID: https://orcid.org/0000-0002-7698-657X)
- Justine Meiller (ORCID: https://orcid.org/0000-0002-2997-4007)
- Laura Breen (ORCID: https://orcid.org/0000-0001-5146-9333)
- Bryan T. Hennessy (ORCID: https://orcid.org/0000-0002-7871-6477)
- Lorraine O’Driscoll (ORCID: https://orcid.org/0000-0002-9860-8262)
- Alacoque L. Browne
- Denis M. Collins (ORCID: https://orcid.org/0000-0003-1043-6169)
- John Paul Crown (ORCID: https://orcid.org/0000-0002-3125-7613)
- Mattia Cremona (ORCID: https://orcid.org/0000-0003-3000-6246)
- Sandra Roche (ORCID: https://orcid.org/0000-0002-4363-4607)
- Neil T. Conlon (ORCID: https://orcid.org/0000-0001-5921-7114)
- Lisa D. Eli (ORCID: https://orcid.org/0000-0003-3896-0966)
- Fiona O’Neill (ORCID: https://orcid.org/0000-0002-6935-5171)
- Johanna Gaubatz
Institutions
- Royal College of Surgeons in Ireland (IE)
- Trinity College Dublin (IE)
- St. Vincent's University Hospital (IE)
- Puma Biotechnology (United States) (US)
- Dublin City University (IE)
Publication Details
- Journal
- Translational Oncology
- Published
- 2024-08-26
- DOI
- https://doi.org/10.1016/j.tranon.2024.102073
- Citations
- 4
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- Puma Biotechnology
- Irish Research Council